Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Operations: 2014-2024

Historic Cash from Operations for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$87.8 million.

  • Viking Therapeutics' Cash from Operations fell 328.03% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.6 million, marking a year-over-year decrease of 202.46%. This contributed to the annual value of -$87.8 million for FY2024, which is 19.64% down from last year.
  • Viking Therapeutics' Cash from Operations amounted to -$87.8 million in FY2024, which was down 19.64% from -$73.4 million recorded in FY2023.
  • Viking Therapeutics' 5-year Cash from Operations high stood at -$21.8 million for FY2020, and its period low was -$87.8 million during FY2024.
  • For the 3-year period, Viking Therapeutics' Cash from Operations averaged around -$69.9 million, with its median value being -$73.4 million (2023).
  • As far as peak fluctuations go, Viking Therapeutics' Cash from Operations grew by 12.02% in 2020, and later slumped by 118.51% in 2021.
  • Yearly analysis of 5 years shows Viking Therapeutics' Cash from Operations stood at -$21.8 million in 2020, then plummeted by 118.51% to -$47.6 million in 2021, then fell by 1.70% to -$48.4 million in 2022, then plummeted by 51.61% to -$73.4 million in 2023, then decreased by 19.64% to -$87.8 million in 2024.